Document:

Exclusive License Agreement

 Exhibit 10.26 
 Exclusive License Agreement 
 between 
 The Regents of the University of California 
 and 
 Alsius Corporation 
 for

 Indwelling Heat Exchange Catheter 
 Case No 99-501 
 Table of contents 
  

					
	 Article No.
	  	 Title
	  	Page
	RECITALS	  	2
	 1.
	  	DEFINITIONS	  	3
	 2.
	  	GRANT	  	5
	 3.
	  	LICENSE ISSUE FEE	  	7
	 4.
	  	ROYALTIES	  	7
	 5.
	  	DUE DILIGENCE	  	9
	 6.
	  	PROGRESS AND ROYALTY REPORTS	  	10
	 7.
	  	BOOKS AND RECORDS	  	11
	 8.
	  	LIFE OF THE AGREEMENT	  	12
	 9.
	  	TERMINATION BY THE REGENTS	  	12
	 10.
	  	TERMINATION BY THE LICENSEE	  	13
	 11.
	  	DISPOSITION OF PATENT PRODUCTS ON 1-LAND UPON TERMINATION	  	13
	 12.
	  	USE OF NAMES AND TRADEMARKS	  	13
	 13.
	  	LIMITED WARRANTY	  	14
	 14.
	  	PATENT PROSECUTION AND MAINTENANCE	  	15
	 15.
	  	PATENT MARKING	  	17
	 16.
	  	PATENT INFRINGEMENT	  	17
	 17.
	  	INDEMNIFICATION	  	18
	 18.
	  	NOTICES	  	19
	 19.
	  	ASSIGNABILITY	  	20
	 20.
	  	LATE PAYMENTS	  	20
	 21.
	  	WAIVER	  	21
	 22.
	  	FAILURE TO PERFORM	  	21
	 23.
	  	GOVERNING LAWS	  	21
	 24.
	  	GOVERNMENT APPROVAL OR REGISTRATION	  	21
	 25.
	  	EXPORT CONTROL LAWS	  	21
	 26.
	  	FORCE MAJEURE	  	22
	 27.
	  	CONFIDENTIALITY	  	22
	 28.
	  	MISCELLANEOUS	  	23

  

 i 

 Exclusive License Agreement 
 for 
 Alsius Corp. 
 This license agreement (“Agreement”) is effective this — day of November 1999, by and between The Regents of the University of California (“The Regents”), a California corporation, having its
statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 acting through the offices of The University of California, Los Angeles located at 10945 Le Conte Avenue, Suite 1401, Los Angeles, California
90095-1406, and Alsius Corporation (“Licensee”), a California corporation, having a principal place of business at 15770 Laguna Canyon Road, Suite 150, Irvine, California 92618. 
 Recitals 
 Whereas, certain inventions, characterized as “Indwelling Heat Exchange
Catheter and Method of Using” (“Invention”), disclosed in UCLA case number LA99-501, useful for brain tissue preservation after stroke or other trauma, as co-invented at the University of California, Los Angeles by Dr. Pierre
Gobin and at Alsius by Scott Evans, Mike Jones, and Wayne Noda: and are claimed in Patent Rights defined below; 
 Whereas, Dr. Pierre
Gobin is an employee of the University of California, Los Angeles and has assigned his rights in the invention to the Regents; 
 Whereas,
Scott Evans, Mike Jones and Wayne Noda have assigned their rights to Alsius; 
 Whereas, the Licensee is a “small entity” as
defined in 37 CFR Section 1.9 and a “small-business concern” defined in 15 U.S.C. Section 632; 
 Whereas, both parties
recognize that royalties due under this Agreement will be paid on pending patent applications and issued patents; 
 Whereas, the Licensee
has requested certain of The Regents’ rights pursuant to commercializing the Invention; and 
 Whereas, The Regents responded to the
request of the Licensee by granting the following rights to the Licensee. 

 The parties agree as follows: 
 1. Definitions 
 As used in this Agreement, the following terms will have the meaning set forth below:

 1.1 “Patent Rights” means all rights in U.S. patents and patent applications and foreign patents and patent applications assigned wholly or in
part to The Regents, including any reissues, extensions, substitutions, continuations, divisions, and continuations-in-part applications (only to the extent, however, that Dr. Gobin is an inventor of any invention claimed in the continuation in
part applications and that the subject matter is fully supported and enabled by the parent application) based on and including any subject matter claimed in or covered by US. Patent Application Serial Number 09/063, 984, entitled Indwelling Heat
Exchange Catheter and Method of Using Same”, filed April 21, 1998 and assigned to The Regents. 
 1.2 “Patent Products” means:

 i. any kit, composition of matter, material, or product; 
 ii. any kit, composition of matter, material, or product to be used in a manner requiring the performance of the Patent Method; or 
 iii. any kit, composition of matter, material, or product produced by the Patent Method; to the extent that the manufacture, use, or sale of such kit, composition of matter, material, or product, in a particular
country, would infringe, but for a license or ownership rights therein, a claim of an issued and unexpired patent or claim of a pending patent application were it issued as a claim in a patent under Patent Rights in that country in which such patent
has issued or application is pending which claim has not been held unpatentable, invalid or unenforceable by a final decision of a court or other government agency of competent jurisdiction from which no appeal has or can be taken and has not been
admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise. This definition of Patent Products also includes a service either used by the Licensee or provided by the Licensee to its customers when such service
requires the practice of the Patent Method. 
  

 3 

 1.3 “Patent Method” means any process or method covered by the claims of a patent application or patent within
Patent Rights or the use or practice of which would constitute in a particular country a infringement, but for a license or ownership rights therein, of a claim of an issued and unexpired patent or claim of a pending patent application were it
issued as a claim in a patent within Patent Rights in that country in which the Patent Method is used or practiced which claim has not been held unpatentable, invalid or unenforceable by a final decision of a court or other government agency or
competent jurisdiction from which no appeal has or can be taken arid has not been admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise. 
 1.4 “Net Sales” means the gross invoice prices from the sale of Patent Products by the Licensee, an Affiliate, a Joint Venture, or a sublicensee to independent third parties for cash or other forms of
consideration in accordance with generally accepted accounting principles limited by the following deductions (if not already deducted from the gross invoice price and at rates customary within the industry): (a) allowances (actually paid and
limited to rejections, returns, and prompt payment and volume discounts granted to customers of Patent Products, whether in cash or Patent Products in lieu of cash); (b) freight, transport packing, insurance charges associated with
transportation; (c) taxes, tariff, or import/export duties based on sales when included in gross sales, but not value-added taxes or taxes assessed on income derived from such sales; and (d) provisions for uncollectable amounts determined
in accordance with reasonable accounting practices, consistently applied by the selling party, Where the Licensee distributes Patent Products for end use to itself, an Affiliate, a Joint Venture, or a sublicensee, then such distribution will be
considered a sale at the price normally charged to independent third parties, including distributors whose pricing is not controlled by Licensee; and The Regents will be entitled to collect on such royalty in accordance with Paragraph 1.5. Net Sales
for Patent Products that are kits which include a patented catheter licensed hereunder as well as other items such as tubing Sets, temperature probes and water cooling systems, the proprietary rights which are not owned by The Regents shall be
calculated as follows: Net Sales price for a kit for 

  

 4 

 
purposes of royalties equal net price of kit times the ratio of the average gross selling price of a catheter licensed hereunder to the gross selling price
of the kit. 
 1.5 “Affiliate(s)” of the Licensee means any entity which, directly or indirectly, controls the Licensee, is controlled by the
Licensee, or is under common control with the Licensee (“control” for these purposes being defined as the actual, present capacity to elect a majority of the directors of such affiliate, or if not, the power to direct at least forty
percent (40%) of the voting rights entitled to elect directors) provided, however, that in any country where the local law will not permit foreign equity participation of a majority, then an “Affiliate will include any company in which the
Licensee owns or controls, directly or indirectly, the maximum percentage of such outstanding stock or voting rights permitted by local law. Each reference to the Licensee herein will be meant to include its Affiliates. 
  
 1.6 “Joint Venture” means any separate entity established pursuant to a” agreement
between a third party and the Licensee to constitute a vehicle for a joint venture, in which the separate entity manufactures, uses, purchases, sells, or acquires Patent Products from the Licensee. Each reference to the Licensee herein will be meant
to include its Joint Venture(s). 
 1.7 “Sublicensing Income” means income received by Licensee under or on account of Sublicenses. Sublicensing
Income includes income received by way of license issue fee, milestone payments and the like but specifically excludes royalties on the sale or distribution of Licensed Products or the practice of Licensed Methods. Not included in the definition of
Sublicensing income is income received by Licensee as payment or reimbursement for research costs conducted by or for Licensee, including costs associated with materials, equipment, or clinical testing. 
 2. Grant 
 2.1 Subject to the limitations Set forth in this
Agreement, The Regents hereby grants to the Licensee an exclusive world wide right under The Regents’ interest in Patent Rights to make, have made, use, sell, offer for sale, and import Patent Products and to practice the Patent Method.

  

 5 

 2.2 The manufacture of Patent Products and the practice of the Patent Method will be subject to applicable government
importation laws and regulations of a particular country on Patent Products made outside the particular country in which such Patent Products are used or sold. 
 2.3 The Regents also grants to the Licensee the right to issue sublicenses to third parties under the Regents’ interest in Patent Rights to make, have made, use, sell, offer for sale, and import Patent Products and to practice Patent
Method, provided the Licensee retains current exclusive rights thereto under this Agreement. To the extent applicable, such sublicenses will include all of the rights of and obligations due to The Regents (and, if applicable, the United States
Government) that are contained in this Agreement and including payment to The Regents of 25% of Sublicensing Income and payment of royalties at the rates provided for in Article 4 (Royalties). 
 2.4 The Licensee wilt notify The Regents of each sublicense granted hereunder and provide The Regents with a copy of each sublicense. The Licensee will collect and pay
all fees and royalties due The Regents as set forth in Article 4 below and guarantee all such payments due from the sublicensees. The Licensee will require the sublicensees to provide it with progress and royalty reports in accordance with the
provisions, herein, and the Licensee will collect and deliver to The Regents all such reports clue from the sublicensees. 
 2.5 Upon termination of this
Agreement for any reason, The Regents, at its sole discretion, will determine whether any or all sublicenses will be cancelled or assigned to The Regents, 
 2.6 Nothing in this Agreement will be deemed to limit the right of The Regents to publish any and all technical data resulting from any research performed by The Regents relating to the Invention and to make and use the invention, Patent
Product(s), Patent Method(s), and associated technology solely for educational, clinical, and research purposes and for purposes not covered by this Agreement. 
  

 6 

 3. License Issue Fee 
 3.1 As partial consideration for all the rights and licenses granted to the Licensee, the Licensee will pay to The Regents a one-time license issue fee of seven thousand dollars ($7000) within 30 days after the execution of this Agreement
by both parties. 
 3.2 The Licensee will also pay to The Regents a one-time patent issuance fee of five thousand dollars ($5,000) upon issuance of the first
issued U.S. Patent under Patent Rights. 
 3.3 The fees Set forth above are non-refundable, non-creditable, and not an advance against royalties. 

4. Royalties 
 4.1 As further consideration for all the
rights and licenses granted to the Licensee, the Licensee and its sublicensees will pay to The Regents an earned royalty at the rate of two and one half percent (2.5%) based on Net Sales of Patent Products. 
 4.2 Paragraphs. 1 1.2, and 1.3 define Patent Rights, Patent Products, and Patent Method so that royalties will be payable on Patent Products and Patent Methods covered
by both pending patent applications and issued patents. Earned royalties will accrue in each country for the duration of Patent Rights in that country and will be payable to The Regents when Patent Products are invoiced, or if not invoiced, when
delivered to a third party or to itself, art Affiliate, Joint Venture, or the sublicensee in the case where such delivery of the Patent Products to the Licensee, an Affiliate, Joint Venture, or the sublicensee is intended for end use. 
 4.3 Royalties accruing to The Regents will be paid to The Regents quarterly on or before the following dates of each calendar year: 
 February 28 for the calendar quarter ending December 31; 
 May 31 for the calendar quarter ending March 31; 
 August 31 for the calendar quarter ending
June 30; and 
 November 30 for the calendar quarter ending September 30. 
  

 7 

 4.4 Each such payment will be for royalties which accrued up to the most recently completed calendar quarter of the
Licensee. 
 4.5 Beginning in the year of the first sale of a Patent Product, and ending on the expiration of the Patent Rights, the Licensee will pay to The
Regents a minimum annual royalty in the amounts and at the times set forth below: 
 Year 1 $5000 
 Year 2 $10,000 
 Year 3 $15,000 
 Year 4 and Thereafter $20,000 
 This minimum annual royalty
will be paid to The Regents by February 28 of each year and will be credited against the earned royalty due and owing for the calendar year in which the minimum payment was made. 
 4.6 A one-time $100,000 milestone payment will be paid for the first FDA approval of a Patent Product. No other milestone payments are contemplated hereunder for subsequent, if any, FDA approvals of Patent Products.

 4.7 All monies due The Regents will be payable in United Slates funds collectible at par in San Francisco, California. When Patent Products are sold for
monies other than United States dollars, the earned royalties will first be determined in the foreign currency of the country in which such Patent Products were sold and then converted into equivalent United States funds. The exchange rate will be
that rate quoted in the Wall Street Journal on the last business day of the reporting period. 
 4.8 Earned royalties on sales of Patent Products occurring
in any country outside the United States will not be reduced by any taxes, fees, or other charges imposed by the government of such country except those taxes, fees, and charges allowed under the provisions of Paragraph 1.4 (Net Sales). The Licensee
will also be responsible for all bank transfer charges. 
  

 8 

 4.9 Notwithstanding the provisions of Article 26 (Force Majeure) if at any time legal restrictions prevent prompt
remittance of part or all royalties owed to The Regents by the Licensee with respect to any country where a Patent Product is sold or distributed, the Licensee will convert the amount owed to The Regents into United States funds and will pay The
Regents directly from another source of funds for the amount impounded. 
 4.10 In the event that any patent or any claim thereof included within the Patent
Rights is held invalid in a final decision by a court of competent jurisdiction and last resort and from which no appeal has or can be taken, all obligation to pay royalties based on such patent or claim or any claim patentably indistinct therefrom
will cease as of the date of such final decision. The Licensee will not, however, be relieved from paying any royalties that accrued before such decision or that are based on another patent or claim that has not expired or that is not involved in
such decision. 
 5. Due Diligence 
 5.1 The
Licensee shall, upon execution of this Agreement and subject to all applicable laws and regulations, diligently proceed with the development, manufacture, and sale of Patent Products and will earnestly and diligently market the same after execution
of this Agreement and in quantities sufficient to meet the market demands therefore. The Licensee will be entitled to exercise prudent and reasonable business judgment in the manner in which it meets its due diligence obligations hereunder. In no
case, however, will the Licensee be relieved of its obligations to meet the due diligence provisions of this Article. 
 5.2 The Licensee will use reasonable
efforts to obtain all necessary governmental approvals in each country chosen by licensee in its sole discretion for the manufacture, use, and sale of Patent Products. 
 5.3 If the Licensee is unable to perform any of the following 
 5.3(a) Feasibility Study:
Treatment of 10 patients to be completed by July 2000. 
 5.3(b) Multicenter Clinical Trial of 100 patients to be completed by
July 2001 
  

 9 

 5.3(c) FDA/Preapproval to be completed by February 2002; then The Regents will have the
right and option to terminate this Agreement or reduce the exclusive licenses granted to the Licensee to non-exclusive licenses in accordance with the provisions hereof. The exercise of this right and option by The Regents supersedes the rights
granted in Article 2 (Grant). The Licensee may request a one-year extension of time during the term of the License which will not be unreasonably withheld by The Regents upon appropriate justification by Licensee if Licensee fails to meet any one of
the diligence dates set forth above. 
 6. Progress and Royalty Reports 
 6.1 Beginning May 1, 2000 and semi-annually thereafter, the Licensee will submit to The Regents a progress report covering activities by the Licensee related to the development and testing of all Patent Products
and the obtaining of the governmental approvals necessary for marketing them. These progress reports will be provided to The Regents to cover the progress of the research and development of the Patent Products until their first commercial sale in
the United States. 
 6.2 The progress reports submitted under Paragraph 6.1 will include, but not be limited to, the following topics so that The Regents
may be able to determine the progress of the development of Patent Products and may also be able to determine whether or not the Licensee has met its diligence obligations set forth in Article 5 above: 
 6.2(a) Summary of work completed. 
 6.2(b) Key scientific discoveries.

 6.2(c) Summary of work in progress. 
 6.2(d) Current schedule
of anticipated events or milestones. 
 6.2(e) Market introduction date of Patent Products. 
 6.2(f) A summary of resources (dollar value) spent in the reporting period. 
 6.2(g) Activities of the sublicensees, if any.

  

 10 

 6.2(h) Patents flied by Licensee per Paragraph 14.1 
 All reports hereunder shall be handled as a Confidential material by The Regents if so marked. 
 6.3 The Licensee will also
report to The Regents in its immediately subsequent progress and royalty report the date of first commercial sale of a Patent Product(s) In each country. 
 6.4 After the first commercial sale of a Patent Product, the Licensee will provide The Regents with quarterly royalty reports to The Regents on or before each February 28, May 31 August 31, and November 30 of
each year. Each such royalty report will cover the most recently completed calendar quarter of the Licensee (October through December, January through March, April through June, and July through September) and will show: 
 6.4(a) Gross sales and Net Sales of Patent Products sold by the Licensee and reported to the Licensee as sold by its sublicensees during the most recently completed
calendar quarter. 
 6.4(b) Number of Patent Products sold or distributed by the Licensee and reported to the Licensee as sold or distributed by its
sublicensees. 
 6.4(c) Royalties, in U.S. dollars, payable hereunder with respect to Net Sales: and the exchange rates used if any. 
 6.5 If no sales of Patent Products have been made during any reporting period after the first commercial sale of a Patent Product, then a statement to this effect is
required. 
 7. Books and Records 
 7.1 The
Licensee will keep books and records accurately showing all Patent Products manufactured, used, and/or sold under the terms of this Agreement. Such books and records will be preserved for at least five years after the date of the royalty payment to
which they pertain and will be open to inspection by representatives or agents of The Regents at reasonable times to determine the accuracy of the books and records and to determine compliance by the Licensee with the terms of this Agreement.

 7.2 The fees and expenses of representatives of The Regents performing such an examination will be borne by The Regents. However, if an error in royalties
of more than five percent (5%) 

  

 11 

 
of the total royalties due for any year is discovered, then the fees and expenses of these representatives will be borne by the Licensee. 
 8. Life of the Agreement 
 8.1 Unless otherwise terminated by
operation of law or by acts of the parties in accordance with the terms of this Agreement, this Agreement will be in force from the effective date recited on page one and will remain in effect for the life of the last-to-expire patent licensed under
this Agreement, or until the last patent application licensed under this Agreement is abandoned. Any termination of this Agreement will not affect the rights and obligations set forth in the following Articles: 
 Article 7 Books and Records 
 Article 11
Disposition of Patent Products on Hand Upon Termination 
 Article 12 Use of Names and Trademarks 
 Article 17 Indemnification 
 Article 22
Failure to Perform 
 Article 27 Confidentiality 
 8.2 Any termination of this Agreement shall not relieve the Licensee of its obligation to pay any monies due or owing at the time of such termination and shall not relieve any obligations, of either party to the other party, established
prior to termination. 
 9. Termination by The Regents 
 9.1 If the Licensee should violate or fail, to perform any term or covenant of this Agreement, then The Regents may give written notice of such default (“Notice of Default”) to the Licensee. If the Licensee should fail to repair
such default within 60 days after the date of such notice takes effect, The Regents will have the right to terminate this Agreement and the licenses herein by a second written notice (“Notice of Termination”) to the Licensee, If a Notice
of Termination is sent to the Licensee, this Agreement will automatically terminate on the date such notice takes effect. Such termination will not relieve the Licensee of its obligation to pay any royalty or 

  

 12 

 
license fees owing at the time of such termination and will not impair any accrued right of The Regents. These notices will be subject to Article 18
(Notices). 
 10. Termination by the Licensee 
 10.1 The Licensee will have the right at any time to terminate this Agreement in whole or as to any portion of Patent Rights by giving notice in writing to The Regents. Such notice of termination will be subject to Article 18 (Notices) and
termination of this Agreement will be effective 90 days after the effective date thereof. 
 10.2 Any termination pursuant to the above paragraph will not
relieve the Licensee of any obligation or liability accrued hereunder prior to such termination or rescind anything done by the Licensee or any payments made to The Regents hereunder prior to the time such termination becomes effective, and such
termination will not affect in any manner any rights of The Regents arising under this Agreement prior to such termination. Such termination will not relieve the Licensee of its obligation to pa any fees or royalties owing at the time of such
termination and will not impair any accrued right of The Regents. 
 11. Disposition of Patent Products on 1-land Upon Termination 

11.1 Upon termination of this Agreement, the Licensee will continue to have the privilege of selling Patent Products under its own rights in the patents. 

12. Use of Names and Trademarks 
 12.1 Neither party is
permitted to use any name, trade name, trademark or other designation of the other party or its employees (including contraction, abbreviation or simulation of any of the foregoing) in advertising, publicity or other promotional activity. Unless
required by law, Licensee is expressly prohibited from using the name “The Regents of the University of California” or the name of any campus of the University of California. 
 12.2 It is understood that The Regents will be free to release to the inventors and senior administrative officials employed by The Regents the terms of this Agreement upon their request. If such release is made, The
Regents will require that such terms will be kept in confidence in accordance with the provisions of Article 27 (Confidentiality) and not be disclosed 

  

 13 

 
to others. It is further understood that should a third party inquire whether a license to Patent Rights is available, The Regents may disclose the existence
of this Agreement and the extent of the grant in Article 2 (Grant) to such third party, but will not disclose the name of the Licensee, except where The Regents are required to release such information under either the California Public Records Act
or other applicable law. Any release of information by The Regents under this paragraph shall be promptly reported in writing to Licensee. 
 13. Limited Warranty 
 13.1 The Regents warrant to the Licensee that they have the lawful right to grant this license. This license and the
associated Invention, Patent Rights, Patent Products, and Patent Methods are provided WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. THE REGENTS MAKE NO REPRESENTATION OR WARRANTY
THAT THE INVENTION, PATENT RIGHTS, PATENT PRODUCTS, OR PATENT METHOD WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT. 
 13.2 IN NO EVENT WILL THE
REGENTS BE LIABLE FOR ANY INCIDENTAL, SPECIAL, OR CONSEQUENTIAL DAMAGES RESULTING FROM EXERCISE OF THIS LICENSE OR THE USE OF THE INVENTION, PATENT RIGHTS, PATENT METHOD, OR PATENT PRODUCTS. 
 13.3 Nothing in this Agreement will be construed as: 
 13.3(a) A warranty or
representation by The Regents as to the validity, enforceability, or scope of any Patent Rights. 
 13.3(b) A warranty or representation that anything made,
used, sold, or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of patents of third parties. 
 13.3(c)
An obligation to bring or prosecute actions or suits against third parties for patent infringement except as provided in Article 16 (Patent Infringement). 
 13.3(d) Conferring by implication, estoppel, or otherwise any license or rights under any patents of The Regents other than Patent Rights as defined herein, regardless of whether such patents are dominant or subordinate to Patent Rights.

  

 14 

 13.3 (e) An obligation to furnish any know-how not provided in Patent Rights or Patent Products. 
 14. Patent Prosecution and Maintenance 
 14.1 Licensee will,
diligently prosecute and maintain the United States and foreign patents comprising Patent Rights using counsel of its choice, Licensee will promptly inform The Regents of prosecution events and provide the Regents with copies of all relevant
documentation so that The Regents may be currently and promptly informed and apprised of the continuing prosecution, and may comment upon such documentation sufficiently in advance of any initial deadline for filing a response, provided, however,
that if The Regents have not commented upon such documentation prior to the initial deadline for filing a response with the relevant government patent office, Licensee will be free to respond appropriately without consideration of comments by The
Regents, if any. Both parties hereto will keep this documentation in confidence in accordance with the provisions of Article 27 (Confidentiality) herein. Counsel for Licensee will take instructions only from Licensee. 
 So that The Regents may be assured that their patent rights are protected, Licensee will submit each U.S. patent application (under strict
confidentiality) that is to be filed by Licensee to The Regents’ designee for review 30 days prior to filing where practical, regardless of whether Licensee has named an employee of The Regents as inventor on the application. If, in The
Regents’ opinion, an application fails to set forth proper inventorship, Licensee and The Regents will cooperate to resolve any such nonjoinder or misjoinder, hi the event that a dispute over inventorship cannot be resolved by such cooperation,
The Regents shall have the right, but not the obligation, to appoint disinterested patent counsel (i.e., patent counsel who have not previously represented The Regents or Licensee) paid for by Licensee to render an opinion as to the disputed
inventorship. Both parties hereto agree to be bound by any such opinion. 
 14.2 Licensee will use all reasonable, efforts to amend any patent application to
include claims requested by The Regents. 
  

 15 

 14.3 Licensee intends to file, prosecute, and maintain patent applications and patents covered by Patent Rights in
foreign countries if available, and will keep The Regents apprised of its activities in this regard by providing The Regents with a list of elected countries. Should The Regents desire patent protection in countries not elected by Licensee, The
Regents will timely notify Licensee of their desire to file patent applications in such countries. Licensee will cooperate with The Regents to file patent applications in such non-elected countries. The Regents will have the right to tile patent
applications at their own expense in any country Licensee has not included in its list of desired countries, and such applications and resultant patents, if any, will not be included in the licenses granted under this Agreement. 
 14.4 All past, present and future costs of preparing, filing, prosecuting and maintaining all United States and foreign patent applications and all costs and fees
relating to the preparation and filing of patents covered by Patent Rights in Paragraph 1.1 and costs under Paragraph 14.1 will be borne by the Licensee including cost of Regents counsel to review and provide comment on preparation, filing, and
prosecuting of Patent Rights with the exception of the costs discussed above in relation to non-elected countries in Paragraph 13.4, provided that any fees or costs incurred by The Regents in excess of $5,000 for which The Regents expect
reimbursement are preapproved in writing by Licensee, such preapproval is not to be unreasonably withheld by Licensee. Licensee will reimburse The Regents for patent preparation and prosecution costs for this Invention incurred by The Regents prior
to the execution of this Agreement. Such costs will be due upon execution of this Agreement and will be payable at the time that the license issue fee is payable. The costs of all interferences and oppositions will be considered prosecution expenses
and also will be borne by the Licensee. The Licensee will reimburse The Regents for all costs and charges within 30 days following receipt of an itemized invoice from The Regents for same. 
 14.5 Licensee’s obligation to underwrite and to pay all United States and foreign patent costs will continue for as long as this Agreement remains in effect.
Licensee may terminate its obligations to any given patent application or patent upon three months written notice to The 

  

 16 

 
Regents. The Regents will use its best efforts to curtail patent costs chargeable to Licensee under this Agreement after this notice is received from
Licensee. The Regents may continue prosecution or maintenance of these application(s) or patent(s) at its sole discretion and expense, and Licensee will have no further rights or licenses to them. 
 14.6 The Licensee will notify The Regents of any change of its status as a small entity (as defined by the United States Patent and Trademark Office) and of the first
sublicense granted to an entity that does not qualify as a small entity as defined therein. 
 15. Patent Marking 
 15.1 The Licensee will mark all Patent Products made, used, or sold under the terms of this Agreement, or their containers, in accordance with the applicable patent
marking laws. 
 16. Patent Infringement 
 16.1
In the event that either party (but The Regents only through it’s Technology Transfer Officer responsible for this case) learns of the substantial infringement of any patent in Patent Rights, each party will inform, the other in writing and
Licensee will provide The Regents with reasonable evidence of the infringement. During the period and in a jurisdiction where Licensee has exclusive rights under this Agreement, neither party will notify a third party of the infringement of any of
Patent Rights without first obtaining consent of the other party, which consent must not be unreasonably denied. Both parties will use their best efforts to cooperate to terminate the infringement without litigation. 
 16.2 In order to take legal action for infringement, Licensee must request that The Regents join them to take legal action against the infringement of Patent Rights.
This request must be in writing and must include reasonable evidence of the infringement and the damages to Licensee. If the infringing activity has not been abated within 90 days following the effective date of the request, The Regents has the
right to (a) join with the Licensee to commence suit against the infringer or (b) refuse to participate in a suit. The Regents must give notice of its election in writing to Licensee by the end of the 100th day after receiving notice of
the request from Licensee But, should The Regents determine before the 100th day that they do not wish to join 

  

 17 

 
the suit they will notify Licensee as soon as possible. Licensee may thereafter bring suit for patent infringement in its own name if and only if The Regents
elected not to commence Suit and if the infringement occurred during the period and in a jurisdiction where the third party had allegedly infringed Licensee’s exclusive rights under this Agreement. However, in the event Licensee elects to bring
suit in accordance with this Paragraph 16.2, The Regents may thereafter join the suit at its own expense. 
 16.3 Such legal action as is decided upon will
be at the expense of the party on account of whom suit is brought and all recoveries recovered thereby will belong to such party, provided, however, that legal action brought jointly by The Regents and the Licensee and participated in by both will
be at the joint expense of the parties and all recoveries will be allocated in the following order: a) to each party reimbursement in equal amounts of the attorneys costs, fees, and other related expenses to the extent each party paid for such
costs, fees, and expenses until all such costs, fees, and expenses are consumed for each party; and b) any remaining amount shared jointly by them in proportion to the share of expenses paid by each party. 
 16.4 Each party will cooperate with the other in litigation proceedings instituted hereunder but at the expense of the party on account of whom suit is brought. Such
litigation will be controlled by the party bringing the suit, except that The Regents may be represented by counsel of its choice in any suit brought by the Licensee. 
 17. Indemnification 
 17.1 Licensee will (and require its sublicensees to) indemnify, hold harmless, and defend The Regents,
its officers, employees, and agents; the sponsors of the research that led to the Invention; the inventors of any invention covered by patents or patent applications in Patent Rights (including the Patent Products and Patent Method contemplated
thereunder) and their employers against any and all claims, suits, losses, damage, costs, fees, and expenses resulting from or arising out of exercise of this license or any sublicense. This indemnification will include, but will not be limited to,
any product liability. 
  

 18 

 17.2 As a condition to using or selling the Patent Products in humans, Licensee, at its sole cost and expense, will
insure its activities in connection with the work under this Agreement and obtain, keep in force, and maintain insurance as follows: (or an equivalent program of self insurance) 
 17.3 Comprehensive or Commercial Form General Liability Insurance (contractual liability included) with limits as follows: 
  

				
	 Each Occurrence
	  	$	5,000,000
	 Products/Completed Operations Aggregate
	  	$	5,000,000
	 Personal and Advertising Injury
	  	$	5,000,000
	 General Aggregate (commercial form only)
	  	$	5,000,000

 The Licensee will furnish The Regents with certificates of insurance evidencing compliance with all requirements.
Such certificates will: 
 17.3(a) Provide for 30 day advance written notice to The Regents of any modification. 
 17.3(b) Indicate that The Regents has been endorsed as an additional Insured under the coverages referred to under the above. 
 17.3(c) Include a provision that the coverages will be primary and will not participate with nor will be excess over any valid and collectable insurance or program of
self-insurance carried or maintained by The Regents. 
 17.4(d) The Regents will promptly notify the Licensee in writing of any claim or suit brought against
The Regents in respect of which The Regents intends to invoke the provisions of this Article 17 (Indemnification). The Licensee will keep The Regents informed on a current basis of its defense of any claims pursuant to this Article 17
(Indemnification). 
 18. Notices 
 Any notice or
payment required to be given to either party will be deemed to have been properly given and to be effective (a) on the date of delivery if delivered in person; (b) on the date of mailing if mailed by first-class certified mail, postage
paid; or (c) on the date of mailing if mailed by any global express carrier service that requires the recipient to sign the documents 

  

 19 

 
demonstrating the delivery of such notice of payment to the respective addresses given below, or to another address as designated in writing by the party
changing its prior address. 
  

			
	In the case of the Licensee:	  	Alsius Corp.
		  	15770 Laguna Canyon Road, Suite 150
		  	Irvine, CA 92618
		  	Telephone: (949) 453-0150
		  	Facsimile: (949) 453-0702
		  	Attention: John L. Rogitz, Esq.
	In the case of The Regents:	  	The Regents of the University of California
		  	Office of Sponsored Research
		  	Box 951406, 1401 Ueberroth Building
		  	University of California, Los Angeles
		  	Los Angeles, California 90095-1406
		  	Telephone: (310)206-4401
		  	Facsimile: (310) 206-3619
		  	Attention: Director

 19. Assignability 
 19.1 This Agreement is binding upon and will inure to the benefit of The Regents, their successors and assigns, but will be personal to the Licensee and assignable by the Licensee only with the written consent of The
Regents, provided, however, that this Agreement may be assigned by Licensee pursuant to a sale of all or substantially all of Licensee’s stock or assets without any prior approval of The Regents. Any other attempt by Licensee to assign this
Agreement is void unless Licensee obtains the prior written consent of The Regents. 
 20. Late Payments 
 20.1 In the event royalty payments, fees, or patent prosecution costs are not received by The Regents when due, the Licensee will pay to The Regents interest charges at
a rate often percent (10%) simple interest per annum. Such interest will be calculated from the date payment was due until actually received by The Regents. Acceptance by The Regents of any late payment interest from the Licensee under this
Paragraph 20.1 will in no way affect the provision of Article 21 (Waiver) herein. 
  

 20 

 21. Waiver 
 21.1 It is agreed that no waiver by either party hereto of any breach or default of any of the covenants or agreements herein set forth will be deemed a waiver as to any subsequent and/or similar breach or default. 
 22. Failure to Perform 
 22.1 In the event of a failure of
performance due under the terms of this Agreement and if it becomes necessary for either party to undertake legal action against the other on account thereof, then such legal action will be conducted in San Francisco, California, and the prevailing
party wilt be entitled to reasonable attorney’s fees in addition to costs and necessary disbursements. 
 23. Governing Laws 

23.1 THIS AGREEMENT WILL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, excluding any choice of law rules that would direct the
application of the laws of another jurisdiction, but the scope and validity of any patent or patent application will be governed by the applicable laws of the country of such patent or patent application. 
 24. Government Approval or Registration 
 24.1 If this
Agreement or any associated transaction is required by the law of any nation to be either approved or registered with any governmental agency, the Licensee will assume all legal obligations to do so. The Licensee will notify The Regents if it
becomes aware that this Agreement is subject to a United States or foreign government reporting or approval requirement. The Licensee will make all necessary filings and pay all costs including fees, penalties, and all other out-of-pocket costs
associated with such reporting or approval process. 
 25. Export Control Laws 
 25.1 The Licensee will observe all applicable United States and foreign laws with respect to the transfer of Patent Products and related technical data to foreign countries, including, without limitation, the
International Traffic in Arms Regulations (ITAR) and the Export Administration Regulations. 
  

 21 

 26. Force Majeure 
 26.1 The parties to this Agreement will be excused from any performance required hereunder if such performance is rendered impossible or unfeasible due to any acts of God, catastrophes, or other major events beyond their reasonable control,
including, without limitation, war, riot, and insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, look-outs, or other serious labor disputes; and floods, fires, explosions, or other natural disasters. However, any party
to this Agreement will have the right to terminate this Agreement upon 30 days’ prior written notice if either party is unable to fulfill its obligations under this Agreement due to any of the causes mentioned above and such inability continues
for a period of one year. Notices will be subject to Article 18 (Notices). 
 27. Confidentiality 
 27.1 The Licensee and The Regents respectively will treat and maintain the proprietary business, patent prosecution) software, engineering drawings, process and
technical information, and other proprietary information (Proprietary Information”) of the other party in confidence using at least the same degree of care as that party uses to protect its own proprietary information of a like nature for a
period from the date of disclosure until five years after the date of termination of this Agreement. This confidentiality obligation will apply to the information defined as “Data” under the Secrecy Agreement, and such Data will be treated
as Proprietary Information hereunder. 
 27.2 All Proprietary Information will be labeled or marked confidential or as otherwise similarly appropriate by the
disclosing party, or if the Proprietary Information is orally disclosed, it will be reduced to writing or some other physically tangible form, marked and labeled as set forth above by the disclosing party, and delivered to the receiving party within
30 days after the oral disclosure as a record of the disclosure and the confidential nature thereof. Notwithstanding the foregoing, the Licensee and The Regents may use and disclose Proprietary information to its employees, agents, consultants,
contractors, and, in the case of the Licensee, its sublicensees, provided that any such parties are bound by a like duty of confidentiality. 
  

 22 

 27.3 Nothing contained herein will in any way restrict or impair the right of the Licensee or The Regents to use,
disclose, or otherwise deal with any Proprietary Information: 
 27.3(a) That recipient can demonstrate by written records was previously known to it.

 27.3(b) That is now, or becomes in the future, public knowledge other than through acts or omissions of recipient. 
 27.3(c) That is lawfully obtained without restrictions by recipient from sources independent of the disclosing party. 
 27.3(d) That is required to be disclosed to a governmental entity or agency in connection with seeking any governmental or regulatory approval, or pursuant to the lawful
requirement or request of a governmental entity or agency. 
 27.3(e) That The Regents are required to disclose pursuant to the California Public Records Act
or other applicable law. 
 27.4 Upon termination of this Agreement, the Licensee and The Regents will destroy or return to the disclosing party proprietary
information received from the other in its possession within 15 days following the effective date of termination. The Licensee and The Regents will provide each ether, within 30 days following termination, with a Written notice that Proprietary
Information has been returned or destroyed, Each party may, however, retain one copy of Proprietary Information for archival purposes in non-working files. 
 28. Miscellaneous 
 28.1 The headings of the several sections are inserted for convenience of reference only and are not
intended to be a part of or to affect the meaning or interpretation of this Agreement. This Agreement will not be binding upon the parties until it has been signed below on behalf of each party, in which event, it will be effective as of the date
recited on page one. No amendment or modification hereof will be valid or binding upon the parties unless made in writing and signed on behalf of each party. 
 28.2 This Agreement embodies the entire understanding of the parties and will supersede all previous communications, representations or understandings, either oral or written, between the parties relating to the subject matter hereof.

  

 23 

 28.3 In case any of the provisions contained in this Agreement are held to be invalid, illegal, or unenforceable in any
respect, such invalidity, illegality, or unenforceability will not affect any other provisions hereof, but this Agreement will be construed as if such invalid or illegal or unenforceable provisions had never been contained herein. 
 28.4 This Agreement has been negotiated and prepared jointly by both parties and shall not be construed for or against any party but shall be given a fair and reasonable
construction in accordance with the intention of the parties. 
 In witness whereof both The Regents and the Licensee have executed this
Agreement, in duplicate originals, by their respective officers hereunto duly authorized, on the date and year hereinafter written. 
  

									
	ALSIUS CORP.	 		 	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
					
	By	 	/s/ William Worthen	 		 	By	 	/s/ Patricia Brennan
		 	(Signature)	 		 		 	(Signature)
	Name	 	William J. Worthen	 		 	Name:	 	Patricia Brennan
		 	(Please Print)	 		 		 	
	Title	 	President & CEO	 		 	Title:	 	Director, Office of Sponsored Research
	Date	 	2/8/00	 		 	Date	 	11/16/99

  

 24 

 First Amendment 
 To 
 Exclusive License Agreement No. 2000-04-0437 
 For Indwelling Heat Exchange Catheter 
 This Amendment is made and is effective this 25 day of October,
2000 by and between The Regents of the University of California (“The Regents”), a California corporation having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607- 5200, acting through the
offices of The University of California, Los Angeles located at 10920 Wilshire Boulevard, Suite 1200, Los Angeles, California 90024 and Alsius Corporation (“Licensee”), a California corporation having a principal place of business at 15770
Laguna Canyon Road, Suite 150, Irvine, California 92618 and amends License Agreement No, 2000- 04-0437 between The Regents and Alsius in accordance with the terms and conditions of this Amendment. 
 The parties agree as follows: 
 1. Section 1.1 under Definitions shall
be amended to add at the end of the paragraph the following: 
 “Patent applications that fall under the definition of Patent Rights as
defined in Section 1 1 will be automatically be incorporated in arid added to Appendix A and made a part of this agreement.” 
 2. Section 6.1
under Progress and Royalty Reports shall be amended to read: 
 “Beginning October 30, 2000 and semi-annually thereafter, the
Licensee will submit to The Regents a progress report covering activities by the Licensee related to the development and testing of all Patent Products and the obtaining of the governmental approvals necessary for marketing them, These progress
reports will be provided to The Regents to cover the progress of the research and development of the Patent Products until their first commercial sale in the United States.” 
 All other terms and conditions remain the same. 
  

									
	ALSIUS CORPORATION	 		 	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
					
	By:	 	/s/ Arlan L. Alonzo	 		 	By:	 	/s/ Emily Waldron
	Name:	 	Arlyn L. Alonzo	 		 	Name:	 	Emily Waldron
	Title:	 	Sr. I.P. Counsel	 		 	Title:	 	Asst. Director
	Date:	 	10/25/00	 		 	Date:	 	10-25-00

  

 25 

 APPENDIX A 
 Exclusive License Agreement No. 2000-04-0437 
 For Indwelling Heat Exchange Catheter 
  

	1.	Patent Application Serial No, 091133,813 filed August 13, 1998 entitled indwelling Heat Exchange Catheter and Method of Using Same,” (UCLA Case No. LA99-501-2).

  

	2.	Patent Application Serial No. 09/503,014 filed February 11, 2000 entitled “Indwelling Heat Exchange Catheter and Method of Using Same11’ (UCLA Case No.
LA99501-3). 

  

	3.	Patent Application Serial No. 09/546,814 filed April 11, 2000 entitled “Indwelling Heat Exchange Catheter and Method of Using Same,1’ (UCLA Case No, LA99-501-4).

 10/25/00 
  

 26Nonexclusive License Agreement

 Exhibit 10.27 
 NONEXCLUSIVE LICENSE AGREEMENT 
 This Agreement is effective May 14, 1999, between Alsius
Corporation with offices at #5 Jenner, Suite 150, Irvine, CA 92618-3808 (“ALSIUS”) and Baxter Healthcare Corporation, acting through its CardioVascular Group business unit with offices at 17211 Red Hill Avenue, Irvine, CA. 92614
(“BAXTER”). 
 BACKGROUND 
 BAXTER has developed a certain proprietary biological heparin medical treatment known as DURAFLO® (the “DURAFLO Treatment”) which it represents is described in and covered by certain patents owned by BAXTER as identified on Exhibit A
(“Patents”) and certain specifications, methods, processes, systems, and other know-hiow relating to the application of the DURAFLO Treatment to products “(Know-How”) which is confidential, not known in the industry, and owned by
BAXTER. 
 BAXTER desires to license to ALSIUS and ALSIUS desires to obtain from BAXTER a limited nonexclusive, nontransferable license to
apply DURAFLO Treatment to and sell Heat Exchange Catheters (“Field of Use”) manufactured by ALSIUS (“ALSIUS Products”) treated with the DURAFLO Treatment (“Treated ALSIUS Products”) as listed on Exhibit B. 

AGREEMENT 
  

	1.	LICENSE TO DURAFLO TREATMENT. 

 1.1 License to Patents and
Know-How. BAXTER hereby grants to ALSIUS a limited, non-exclusive, non-transferable, world-wide license under the Patents and Know-How to apply the DURAFLO Treatment to ALSIUS Products and to sell Treated ALSIUS Products to its customers including
its distributors or resellers. This limited license is not intended to grant ALSIUS the right to make or sell the DURAFLO Treatment, but is solely a limited right to apply the DURAFLO Treatment purchased from BAXTER to ALSIUS Products and to sell
Treated ALSIUS Products. BAXTER shall have the right to sell the DURAFLO Treatment to other persons and to use the DURAFLO Treatment on its own or a third party’s products, at its sole discretion. BAXTER’s right to license, manufacture,
use, sell or resell the DURAFLO Treatment shall not be limited in any way. 
 1.2 Pricing and Payment. BAXTER shall supply ALSIUS with
DURAFLO Treatment powder necessary for ALSIUS to apply the DURAFLO Treatment to ALSIUS Products, at a price of $39 per gram. ALSIUS shall pay BAXTER for the DURAFLO Treatment powder within one (1) month after shipping and invoicing of the
DURAFLO Treatment powder. Prices for the DURAFLO Treatment powder shall be fixed for the first calendar year of the Agreement. Thereafter, BAXTER may increase the prices based on increases in material costs, but in no event more than 3% per
year. 
 1.3 Know-How Transfer. BAXTER agrees to disclose and transfer to ALSIUS Know-How necessary for ALSIUS to apply the DURAFLO Treatment
to ALSIUS Products and to test and evaluate Treated ALSIUS Products. ALSIUS shall 

 
apply all DURAFLO Treatments to ALSIUS Products at wholly (100%) owned ALSIUS manufacturing facilitates in accordance with the confidentiality
requirements of this Agreement, or at ALSIUS controlled manufacturing facilities which shall be bound by the confidentiality requirements of this Agreement. 
  

	2.	TRADEMARK LICENSE. 

 2.1 BAXTER further grants to ALSIUS a
non-exclusive, non-transferable license to use the trademark DURAFLO® in connection with Treated ALSIUS Products. ALSIUS agrees to label Treated ALSIUS Products with the DURAFLO® trademark and to identify DURAFLO® as a trademark of Baxter International Inc., both on the product container, and any product packaging, Any and all uses of the DURAFLO® trademark will be accompanied by an appropriate
trademark notice, consisting of an encircled R, with a statement to the effect that “DURAFLO® is a registered trademark of BAXTER INTERNATIONAL INC.” 
 2.2 In order
for ALSIUS to maintain its trademark license, ALSIUS agrees that the Treated ALSIUS Products in their finished form shall be of high standard and quality so as to protect and enhance the goodwill pertaining to the DURAFLO Treatment and shall be of a
quality consistent with the quality of products manufactured and sold by BAXTER having the DURAFLO Treatment applied thereon. Upon BAXTER’s request, but not more than once per year, ALSIUS agrees to provide BAXTER with samples of the Treated
ALSIUS Products in their finished form, for BAXTER’S review and approval to ensure ongoing quality of the Treated ALSIUS Products. Should BAXTER at any time determine that the ongoing quality of the Treated ALSIUS Products in their finished
form do not adhere to BAXTER’s quality standards, ALSIUS license to the DURAFLO® trademark may be terminated by BAXTER at BAXTER’s sole discretion, 
  

	3.	UPFRONT LICENSE FEE AND DEVELOPMENT FEE. 

 3.1 ALSIUS
agrees to pay BAXTER a license fee of $100,000, payable as follows: 
  

	 	(a)	$5,000 - Feasibility payment. 

 (was previously paid to
BAXTER by Alsius Corporation) 
  

	 	(b)	$20,000 - On approval of license agreement by ALSIUS and BAXTER. 

  

	 	(c)	$25,000 - Submission of PMA or 510 (k) to US. regulatory authority. 

  

	 	(d)	$25,000 - 1st commercial sale inside the United States. 

  

	 	(e)	$25,000 - 1st commercial sale outside the United States. 

  

	4.	ROYALTY. 

 4.1 ALSIUS agrees to pay BAXTER a royalty on the
Net Selling Price of each Treated ALSIUS Product sold by ALSIUS, at the royalty rates indicated in the 

  

 2 

 
attached Exhibit C. Net Selling Price shall mean the gross billing price which ALSIUS charges to its customers, including distributors where ALSIUS does not
control the prices set by such Distributors, for Treated ALSIUS Products less, if included in gross billing price, any sales, use, occupation and excise tax paid, incurred or levied on such sales. The royalty payment shall be made on the basis of
calendar quarters beginning with the calendar quarter in which the First Commercial Sale occurs, and shall be payable within thirty (30) days of the end of each such quarter. ALSIUS agrees to pay BAXTER a minimum royalty of $5,000 per calendar
quarter, payable within 30 days of the end of the quarter, beginning with the second quarter after the first commercial sale of the product. “First Commercial Sale” as used herein shall mean: (1) in the United States, the first arms
length sale to third party, including distributors where ALSIUS does not control the pricing set by such distributors, of a Treated ALSIUS Product which has been approved by the appropriate Federal and State governmental agencies for distribution
and sale; and (2) outside the United States, the first arms length sale to a third party of a Treated ALSIUS Product. ALSIUS and its affiliates, if applicable, shall maintain books that account for its sales of Treated ALSIUS Products.

 4.2 In the event that any Treated ALSIUS Products are sold in a kit that includes products other than those identified in Exhibit B, then
the Net Selling Price for royalty purposes shall be computed using the average Net Selling Price for Treated ALSIUS Products sold separately in the same calendar quarter. If the Treated ALSIUS Product is not sold separately, then the Net Selling
Price for the Treated ALSIUS Product shall be determined by using reasonable market pricing for similar products sold on an individual basis by other entities, with the reasonable market price for the Treated ALSIUS Products to be based on the
average market price of such other similar products. 
 4.3 ALSIUS agrees to make payment to BAXTER by checks mailed to BAXTER at the address
set forth below or at such other address as BAXTER may specify for that purpose. ALSIUS agrees to submit to BAXTER, with each royalty payment, a written report showing the number of Treated ALSIUS Products sold in the quarter and the Net Selling
Price for such Treated ALSIUS Products. All payments made to BAXTER pursuant to this Agreement shall be made in United States dollars; and all international and domestic sales of Treated ALSIUS Products shall be reported in equivalent United States
dollars. 
 4.4 ALSIUS shall keep full and accurate records and books of account containing all particulars necessary for showing the amounts
of royalties due BAXTER hereunder. At all reasonable times for a period of not more than two (2) years after the end of each reporting year, not to exceed once each year and upon ten (10) business days prior written notice to ALSIUS, the
books and records relating to sales of the Treated ALSIUS Products shall be open to inspection by BAXTER’s duly appointed independent Certified Public Accountants, who may make such confidential inspection of such records and books of account
as is necessary to verify the computation of royalties due to BAXTER. Any adjustment in the amount due to BAXTER on account of overpayment or underpayment of royalties shall be made at the next date when royalty payments are called for under the
Agreement. In the event that there is an underpayment in the royalties which exceeds ten (10) percent of the actual royalties paid during the period of time 

  

 3 

 
under inspection, then ALSIUS shall reimburse BAXTER for all costs incurred by BAXTER in conducting such inspection. 
  

	5.	ORDERS, FORECASTS AND SHIPPING. 

 5.1 BAXTER agrees to
supply ALSIUS with the DURAFLO Treatment in quantities specified by ALSIUS; provided that the minimum quantity for each purchase order shall be one hundred (100) grams of powder and that orders must be in increments of fifty (50) whole
grams. 
 5.2 ALSIUS shall give BAXTER quarterly rolling forecasts twelve (12) months in advance. ALSIUS shall issue firm Purchase
Orders no less than one (1) quarter prior to specified delivery dates for quantities within forecasted amounts using the purchase order set forth in Exhibit E (the “Purchase Order”). BAXTER shall acknowledge promptly each ALSIUS
Purchase Order in writing and confirm delivery dates to destinations specified by ALSIUS. BAXTER shall not be liable for failure or delay in filling ALSIUS orders because of any cause beyond the control of and occurring without the fault of BAXTER;
provided, however, that BAXTER shall notify ALSIUS promptly of anticipated delays and shall use reasonable efforts to fill such orders as soon as possible. 
 5.3 BAXTER shall ship the DURAFLO Treatment powder BAXTER’s facility via mutually agreed upon carriers. ALSIUS shall pay all normal freight charges. 
  

	6.	SALES TRAINING. 

 BAXTER, at ALSIUS request and at ALSIUS
expense, will provide training for ALSIUS sales force regarding the DURAFLO Treatment, as well as provide ALSIUS with existing marketing and technical information concerning the DURAFLO Treatment for ALSIUS use in marketing Treated ALSIUS Products.

  

	7.	CONFIDENTIALITY. 

 ALSIUS and BAXTER realize that some
information received by one party from the other pursuant to this Agreement may be confidential. It is therefore agreed that any information received by one party from the other which is in writing or promptly reduced to writing, within thirty
(30) days of disclosure, and clearly designated as “CONFIDENTIAL”, shall not be disclosed by the receiving party to any third party and shall not be used by the receiving party for purposes other than those contemplated by this
Agreement during the term of this Agreement and for a period of three (3) years from and after the termination of this Agreement, unless the other party consents in writing to such disclosure and/or use. The receiving party shall use the same
degree of care with respect to such information that it uses with respect to its own information which it intends to maintain proprietary and confidential. However, nothing in this Agreement shall prevent the receiving party from exercising any
legal rights to disclose, use, duplicate, or publish any such information - - 
  

 4 

	 	(a)	which was in the public domain at the time of the disclosure to the receiving party, or which thereafter fell into the public domain without any fault of the receiving party;

  

	 	(b)	which the receiving party rightfully had in its possession prior to the disclosure as evidenced in writing; 

  

	 	(c)	which the receiving party lawfully obtained without restriction from a third party who is not under any confidentiality obligations to the disclosing party;

  

	 	(d)	which, in the case of an oral disclosure, shall not have been subsequently confirmed in writing to the receiving party within thirty (30) days after such oral disclosure; or

  

	 	(e)	which is independently developed by the receiving party without the benefit of such disclosure, 

 Either party may disclose the existence of the Agreement and the Field of Use specified in the Background section of this Agreement, but not the terms of this Agreement. 
  

	8.	TERM. 

 Unless sooner terminated as otherwise provided
herein, this Agreement shall remain in full force and effect for seven (7) years. 
  

	9.	TERMINATION. 

 Either party may terminate this Agreement
for any material breach by the other party thirty (30) days after written notice containing details of the breach if the breach remains uncured at the end of the notice period. Either party may terminate this Agreement effective immediately
with written notice if the other party shall file for bankruptcy, shall be adjudicated bankrupt, shall take advantage of applicable insolvency laws, shall make an assignment for the benefit of creditors, shall be dissolved or shall have a receiver
appointed for its property. BAXTER shall have the rights to terminate this Agreement upon sixty (60) days prior written notice if ALSIUS discontinues developing, manufacturing or selling Treated ALSIUS Products. Upon termination of this
Agreement, ALSIUS agrees to immediately cease using the DURAFLO® trademark in any manner and for any purpose and to immediately cease all use of the DURAFLO Treatment powder provided by BAXTER. No termination of this Agreement shall affect the rights of BAXTER to earned royalties
due and owing and to statements of account and to conduct inspections of books and records, to and including the date of termination. Sections 7, 13, 14, 15, and 18 shall survive any termination of this Agreement. 
  

	10.	PRODUCT CHANGES. 

 10.1 DURAFLO Treatment Powder Changes.
BAXTER shall notify ALSIUS six (6) months in advance and in writing of any proposed change in the DURAFLO 

  

 5 

 
Treatment which would materially affect ALSIUS regulatory approval to sell Treated ALSIUS Products. ALSIUS may at that time provide a forecast of ALSIUS
powder requirements for the eighteen (18) month period following the date of such notice to ALSIUS. not to exceed two times the forecast for the previous eighteen (18) month period. ALSIUS shall issue a single firm purchase order for that
amount. In the event such changes are unacceptable to ALSIUS, ALSIUS shall have the right to terminate this Agreement, effective as of the date of implementation of such changes. 
  

	11.	REGULATORY RESPONSIBILITY AND LABELING. 

 Except as
otherwise provided in this Agreement, ALSIUS shall be responsible, at its sole expense, for complying with all applicable regulatory requirements relating to the sale or use of the ALSIUS Products and Treated ALSIUS Products worldwide, including
premarket filings and other requirements of the United States Food and Drug Administration. ALSIUS, at its expense shall produce and provide all artwork, advertising materials, labeling, product inserts and packaging for the Treated ALSIUS Products;
provided, however, that ALSIUS shall obtain BAXTER’s prior written approval for such artwork, advertising materials, labeling, product inserts and packaging as they relate to the DURAFLO Treatment, and for any claims made about the DURAFLO
Treatment. Each use of a trademark, trade name or logo owned or used by BAXTER on or in connection with the DURAFLO Treatment on the Treated ALSIUS Products shall inure to the benefit of BAXTER and its parent company. Should any such use vest in
ALSIUS any rights in any such trademark, trade name or logo, ALSIUS shall transfer such rights to BAXTER or its designee upon request of BAXTER. Except as provided in this Agreement, ALSIUS shall not use any trademark, trade name or logo owned by
BAXTER or any confusingly similar trademark, trade name or logo during or after the term of this Agreement. 
  

	12.	QUALITY CONTROL. 

 12.1 The DURAFLO Treatment powder sold
to ALSIUS shall be subjected to quality control inspection by BAXTER in accordance with BAXTER’s quality control standards and system. While nothing herein provides ALSIUS the right to see, review, or inspect any production process regarded as
proprietary by BAXTER, BAXTER shall upon prior written notice permit ALSIUS to review no more than once a year BAXTER’S production and quality control procedures and records and to visit BAXTER’s facilities at reasonable times with a
representative of BAXTER present in order to assure satisfaction of the requirements of this Agreement as those requirements relate to quality control and as may be necessary to ensure compliance with any regulatory requirements. Each party will
bear its own expenses relating to any such review. BAXTER also agrees to instruct ALSIUS personnel in quality control test operations. 
 12.2 Upon request by ALSIUS, BAXTER shall provide ALSIUS with information necessary for and shall work with ALSIUS to determine the sterilization parameters necessary to maintain the quality of the DURAFLO Treatment on the Treated ALSIUS
Products. ALSIUS will sterilize Treated ALSIUS Products in accordance with 

  

 6 

 
the sterilization parameters. ALSIUS acknowledges that treated ALSIUS Products may not be resterilized because any resterilization may impact product quality
and integrity. ALSIUS shall indicate in the labeling for Treated ALSIUS Products, in a manner sufficient to notify all customers, purchasers or distributors, that Treated ALSIUS Products ma not be resterilized by such customers, purchasers, or
distributors. 
 12.3 ALSIUS shall inspect or audit the Treated ALSIUS Products for integrity and adherence to their specifications, and the
Treated ALSIUS Products shall be subjected to quality control inspection by ALSIUS in accordance with ALSIUS quality control standards and system before selling Treated ALSIUS Products. ALSIUS shall permit BAXTER to review periodically ALSIUS
production and quality control procedures and records in order to assure quality pertaining to the DURAFLO Treatment on the Treated ALSIUS Products and satisfaction of the requirements of this Agreement. If any customer of ALSIUS rejects or returns
Treated ALSIUS Products to ALSIUS as a result of performance problems related to the DURAFLO Treatment, ALSIUS shall notify BAXTER in writing within fifteen (15) days. 
 12.4 In the event that either party receives any complaint regarding the DURAFLO Treatment, it shall notify the other party promptly. BAXTER will be
responsible for evaluating these complaints and responding to ALSIUS in writing. ALSIUS will make a preliminary evaluation of each complaint it receives and will conduct all follow-up and communication which it deems appropriate. 
 12.5 BAXTER will use commercially reasonable efforts to maintain BAXTER’s ISO 9000 certification. Should BAXTER lose ISO 9000 certification; BAXTER
will have a period of six (6) months to regain certification. If BAXTER fails to regain certification within such period of time, ALSIUS shall have the right to terminate this Agreement. 
  

	13.	WARRANTIES. 

 13.1 BAXTER WARRANTS THAT IT POSSESSES GOOD
AND MARKETABLE TITLE TO THE DURAFLO TREATMENT FOR APPLICATION TO ALSIUS PRODUCTS AND THAT THE DURAFLO TREATMENT HAS BEEN MANUFACTURED IN ACCORDANCE WITH GOOD MANUFACTURING PRACTICES. THERE ARE NO OTHER EXPRESSED OR IMPLIED WARRANTIES, INCLUDING ANY
WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. BAXTER’S SOLE OBLIGATION AND PURCHASER’S EXCLUSIVE REMEDY FOR BREACH OF ANY WARRANTY SHALL BE A CREDIT OR REFUND OF THE ROYALTY PAID TO TREAT SUCH ALSIUS PRODUCT. BAXTER
SHALL NOT BE LIABLE FOR PROXIMATE, INCIDENTAL OR CONSEQUENTIAL DAMAGES. 
 13.2 ALSIUS and BAXTER each represent and warrant to the other
that they have full power and authority to enter into this Agreement and to carry out the transactions contemplated hereby and that all necessary corporate action has been duly taken in this regard. 
  

 7 

	14.	INDEMNIFICATION AND LIMITATION OF LIABILITY. 

 14.1 ALSIUS
has represented to BAXTER that it has the capability to perform and ALSIUS has agreed to perform complete quality testing of Treated ALSIUS Products prior to sale. Consequently, except as provided in Paragraph 13 above, BAXTER disclaims any and all
liability that may result from the sale or use of Treated ALSIUS Products. 
 14.2 ALSIUS hereby indemnifies and agrees to defend and to hold
BAXTER, its Successors affiliates, assigns, customers, and users of the ALSIUS Products and Treated ALSIUS Products harmless from and against all claims, liabilities, losses or expenses to the extent arising out of or in connection with the design,
manufacture, packaging, sale or use of the ALSIUS Products or Treated ALSIUS Products, or any other negligent act or omission of ALSIUS. ALSIUS shall obtain and keep in force during the term of this Agreement general comprehensive liability
insurance covering each occurrence of bodily injury and property damage in an amount of not less than $3,000,000 combined single limit with special endorsements providing coverage for (i) Products and Completed Operations Liability, and
(ii) Blanket Contractual Liability including an additional endorsement deleting the Contractual Liability exclusion for Products and Completed Operation Liability. The insurance policy shall be endorsed to provide for written notification to
BAXTER by the insurer not less than thirty (30) days prior to cancellation, expiration or modification. A certificate of insurance evidencing compliance with this Section and referencing this Agreement shall be furnished to BAXTER by ALSIUS
within sixty (60) days of this Agreement’s effective date. 
  

	15.	PATENTS MODIFICATIONS AND IMPROVEMENTS. 

 15.1 All
modifications and/or improvements to the Patents or Know-How relating to the compositions, specifications, methods of application, processes, systems of the DURAFLO Treatment (including the use of the DURAFLO Treatment with ALSIUS Products or other
products) which are conceived and/or reduced to practice solely by ALSIUS, or jointly by ALSIUS and BAXTER, during the term of this Agreement shall be owned jointly by ALSIUS and BAXTER, provided that neither ALSIUS nor BAXTER may transfer their
respective interest in any of the modifications and/or improvements to any other party without the prior written approval of the other. ALSIUS agrees to promptly disclose in writing to BAXTER any such modifications and improvements. BAXTER shall
have the sole right, at its expense, to file any patent and/or copyright applications on such modifications and/or improvements in any country in the world in which BAXTER, in its sole discretion, decides to tile such applications. 
 15.2 BAXTER agrees to prosecute any such patent and/or copyright applications it has decided to file, at its own expense. ALSIUS agrees to assist BAXTER
in the preparation and prosecution of any such application, including but not limited to (a) providing all documentation to enable BAXTER to prepare, file and prosecute any such applications, (b) making its employees available to execute
all papers and do all things which may be necessary or advisable, in the opinion of BAXTER, to prepare, file 

  

 8 

 
and prosecute such applications, and (c) execute all papers and do all things which may be necessary or advisable, in the opinion of BAXTER, to evidence
the joint ownership rights in BAXTER, or its designee, of the modification and/or improvement. 
  

	16.	PRODUCT RECALL. 

 In the event ALSIUS decides to recall any
Treated ALSIUS Product for any reason related in whole or in part to the DURAFLO Treatment, ALSIUS will immediately notify BAXTER of such proposed recall, including the reasons for such recall and the proposed actions for effectuating the recall. In
the event that the recall is made because of a deficiency the DURAFLO Treatment outside of ALSIUS control, BAXTER shall bear reasonable costs and expenses of such recall up to the amount paid by ALSIUS in royalties, provided that ALSIUS first
notifies BAXTER of the proposed actions for effectuating the recall and that BAXTER agrees with such proposed actions. ALSIUS shall maintain complete and accurate records, for such periods as may be required by applicable law, of all the Products
sold by it. The parties will cooperate fully with each other in effectuating any recall of the Products, including communications with any purchasers or users. 
  

	17.	COMPLIANCE WITH LAW. 

 BAXTER and ALSIUS mutually represent
that they are and will remain in material compliance with all applicable federal, state and local laws, regulations and orders applicable to the subject matter of this agreement. 
  

	18.	OTHER PROVISIONS. 

 18.1 This Agreement contains the entire
agreement between the parties relating to the DURAFLO Treatment and all prior understandings between the parties relating to the DURAFLO Treatment are superseded by this Agreement. None of the terms of this Agreement shall be deemed to be waived or
amended by either party unless such a waiver or amendment specifically references this Agreement and is in writing signed by the party to be bound. 
 18.2 All notices and demands required or permitted to be given or made pursuant to this Agreement shall be in writing and shall be effective when personally given or made or when placed in an envelope and deposited in the United States mail
postage prepaid, addressed as follows: 
  

			
	If to BAXTER:	  	If to ALSIUS:
		
	Baxter Healthcare Corporation	  	Alsius Corporation
	Cardio Vascular Group	  	#5 Jenner, Suite 150
	17211 Red Hill Avenue	  	Irvine, CA 92618-3808
	Irvine, CA 92614	  	 Attn: John Rogitz, Esq.

	 Attn: Jay Wertheim
	  	

  

 9 

 or to such other address as to which either party may notify the other. 
 18.3 This Agreement may not be assigned without the written consent of the other party, except that this Agreement may be assigned by either party
without consent to the purchaser of substantially all the assets of that party’s business to which this Agreement relates. Any attempted assignment which does not comply with the terms of this Section shall be void. 
 18.4 This Agreement is deemed to have been executed in and shall be governed by and construed according to the laws of the State of California and
jurisdiction for nay dispute between the parties arising from this Agreement shall be exclusively in the State of California. If particular portions of this Agreement are ruled unenforceable, such portions shall be deleted and all other terms and
conditions of this Agreement shall remain in full force and effect. 
 18.5 If either party fails to fulfill its obligations hereunder, when
such failure is due to an act of God, other actions such as fire, flood, civil commotion, riot, war (declared and undeclared), revolution, action by government including delays in obtaining government approvals, embargoes, then said failure shall be
excused for the duration of said event 
 IN WITNESS WHEREOF, authorized representatives of the parties have executed this Agreement.

  

									
	 BAXTER HEALTHCARE CORPORATION
 Cardio Vascular Group
	 		 	 ALSIUS CORPORATION

					
	 By: 
	 	 /s/ Illegible
	 		 	 By: 
	 	 /s/ William Worthen

	 Title: 
	 	 VP of Business Dev.
	 		 	 Title: 
	 	 President & CEO

	 Date: 5/17/99
	 		 	 Date: 5/14/99

  

 10 

 EXHIBIT A 
 Patents 
 US Patent No. 5,047,020 
 EPO No. 0231573 — West Germany, France, United Kingdom 
 Canada — 128947 
 Japan — 1749399 
  

 11 

 EXHIBIT B 
 (Alsius to complete) 
  

	•	 	COOL LINE TM 

  

	•	 	SQUID TM 

  

 12 

 EXHIBIT C 
  

			
	 0 - 10,000 units
	    	3.5% of Net Selling Price
		
	 10,001 - 25,000 units
	    	3.0% of Net Selling Price
		
	 25,001 - 50,000 units
	    	2.5% of Net Selling Price
		
	 Over 50,000 units
	    	2.0% of Net Selling Price

  

 13 

 

 
 July 14, 2006 
 Mike Ameli 
 V. P. Manufacturing 
 Alsius Corporation 
 15770 Laguna Canyon Road, Suite 150 
 Irvine, CA 92618 
  

	 	Re:	DURAFLO License Agreement 

 Dear Mike: 
 As you are aware, the DURAFLO license agreement, dated May 14, 1999, between Alsius Corporation and Baxter Healthcare Corporation (now Edwards)
expired on May 14, 2006. Under the terms of the license agreement, Alsius agreed to cease using the DURAFLO trademark and to cease using the DURAFLO powder upon termination of the agreement. Subsequent to the expiration of the agreement, you
advised us that Alsius has a remaining inventory of DURAFLO powder sufficient to last for the next 18-24 months (based on the current rate of use for application on heat exchange catheters). You further advised us that Alsius desires to use the
remaining inventory such that Alsius’ manufacture of heat exchange catheters is not disrupted, whichever comes first. 
 Per your
request we hereby authorize Alsius to continue using the DURAFLO trademark and to continue applying DURAFLO to the Alsius products in a manner consistent with the terms of the license agreement for a period of 24 months (i.e., until July 12,
2008) or until the remaining inventory of DURAFLO powder is depleted. 
 If you need any further assistance or clarification, please let me
know. 
  

	
	Best regards –
	
	/s/ David L. Hauser
	David L. Hauser
	Patent Counsel

 DLH:ms 
 Edwards Lifesciences LLC 
 One Edwards Way - Irvine, CA USA - 92614 
 Phone: 949.250.2500 - Fax: 949.250.2525 - www.edwards.com 
 Direct Line: 949-250-6878 Direct Fax: 949-250-6850 Email: david_hauser@edwards.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}]]